Keith D Wilner

Publication Activity (10 Years)

Years Active: 2020-2021
Publications (10 Years): 3

Top Topics

Randomized Controlled Trial

Tyrosine Kinase

Advanced Non Small Cell Lung Cancer

Top Venues

Future oncology (London, England)

This page only lists publications with an associated author ORCID identifier.

Publications

Gregory J Riely, Myung-Ju Ahn, Enriqueta Felip Font, Suresh R Ramalingam, Egbert F Smit, Anne S Tsao, Ann Alcasid, Tiziana Usari, Paul S Wissel, Keith D Wilner, Bruce E Johnson
Encorafenib plus binimetinib in patients with BRAF V600 -mutant non-small cell lung cancer: phase II PHAROS study design. Future oncology (London, England) 18 (7) (2021)
MeganS Farris, Kelly A Larkin-Kaiser, Tayler D Scory, Devon Boyne, Keith D Wilner, Malaïka Pastel, Joseph Christopher Cappelleri, Jasmina I Ivanova
Network meta analysis of first-line therapy for advanced EGFR mutation positive non-small-cell lung cancer: updated overall survival. Future oncology (London, England) 16 (36) (2020)
Kazuhiko Nakagawa, Koichi Matsumura, Tayler D Scory, Megan S Farris, Kelly A Larkin-Kaiser, Hironori Kikkawa, Jasmina I Ivanova, Keith D Wilner
Indirect analysis of first-line therapy for advanced non-small-cell lung cancer with activating mutations in a Japanese population. Future oncology (London, England) 17 (1) (2020)